LRFN5 and OLFM4 in Bipolar Disorder

Sex: All

Ages: 18 Years – 65 Years

Healthy volunteers: Yes

Enrollment: 72

Sponsor: Elazığ Mental Health and Diseases Hospital

Location: Elazığ Mental Health and Diseases Hospital Psychiatry Clinic Elâzığ Elâzığ

Summary

This cross-sectional observational case-control study evaluated serum levels of leucine-rich repeat and fibronectin type III domain-containing protein 5 (LRFN5) and olfactomedin-4 (OLFM4) in subjects with bipolar disorder (BD) during acute manic episodes and in healthy controls (HC). The study also assessed systemic inflammation using the Aggregate Index of Systemic Inflammation (AISI) and examined associations between biomarkers and clinical symptom severity, including Young Mania Rating Scale (YMRS) and Beck Depression Inventory (BDI) scores. The study aimed to investigate the potential interaction between synaptic dysregulation and immunoinflammatory abnormalities in BD.

Eligibility Criteria

1. For Bipolar Disorder (BD) Group: \*Inclusion Criteria: * Diagnosis of BD according to DSM-5-TR * Acute manic episode * Medication-free for at least one month prior to admission * Age ≥ 18 years and \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07434414). StuddyBuddy aggregates publicly available trial information.